LLY 16 min read

Eli Lilly and Company (LLY) — Investment Tree v1

Stage 7 final essay. Bilingual companion: tree_v1_zh.md. Date: 2026-05-30 (R2 re-anchor) · Anchor price: $1,105.00 (2026-05-29 close; 52-wk $623.78-$1,149.10) · Forward PE: ~29.7× FY2026E ($36.98) / ~24.5× FY2027E ($45.12) · Dividend yield: ~0.61% Archetype: GLP-1 cash-compounder with AI-bio option + IRA/biosimilar tail-risk overhang. Closest analogues: Gilead 2014-2018 (single-franchise dominant pharma w/ payer overhang) + AbbVie 2017-2022 (Humira-pre-biosimilar w/ executed pipeline pivot).

SOURCE QUALITY: R2-VERIFIED (2026-05-30). FY2025 financials Tier-A (10-K accn 0000059478-26-000013, filed 2026-02-12) and Q1 2026 Tier-A (10-Q accn 0000059478-26-000045, filed 2026-04-30); price/multiples Tier-B (2026-05-29). Supersedes the 2026-05-19 GENERATE-mode scaffold, which anchored at $760 (a +45% understatement vs the real $1,105) AND understated the business ~25% (revenue $50-55B vs the actual $65.2B; incretin $26-30B vs $36.5B). See evidence_2026-05-30.jsonl + update_2026-05-30.md. Pharma structural-tail claims (persistence, net pricing, IRA, biosimilar timing) remain forward/uncertain; only those carry analytical (†) marking now. Owner domain caveat (corporate banker, not pharma specialist) still informs the conservative sizing cap.

0. Company Fundamentals — what Eli Lilly is and how it earns

Figures FY2025 (calendar 2025) unless noted.

What it is & how it earns. Eli Lilly is a global pharmaceutical company whose economics are now dominated by the incretin/GLP-1 franchise — Mounjaro (tirzepatide for type-2 diabetes) and Zepbound (same molecule, for obesity), which together earned $36.5B in FY2025 (+122% YoY), ~56% of the $65.2B total revenue (+45%). The rest comes from oncology (Verzenio $5.7B), immunology (Taltz), neuroscience (Kisunla for Alzheimer's) and legacy diabetes products. Demand is supply-constrained: manufacturing capacity, not patient demand, is the gating variable, so revenue tracks how fast Lilly can build peptide fill-finish capacity.

Cash-flow anatomy. Branded-pharma gross margin is high (~83%, with a 40.4% operating margin in FY2025), but an unprecedented manufacturing-capex wave plus large acquired-IPR&D charges have held free cash flow well below what the margin implies:

(Operating cash flow and FCF are approximate — data sources diverge materially on Lilly's OCF because of the accounting for large acquired-IPR&D charges; capex is the cleanly reported line. Confirm against the 10-K cash-flow statement before load-bearing use.) The capex line is rising fast (Lilly has announced a >$50B multi-year US buildout), so even at ~83% gross margin, FCF conversion stays compressed until the capacity wave normalizes.

Balance sheet & capital allocation. Cash & equivalents were ~$7.3B at year-end 2025 against ~$42.5B total debt (≈$35B net debt), elevated post-Catalent ($16.5B) but solidly investment-grade. The dividend is $6.92/share annualized (~0.6% yield) with a 30-plus-year increase history; buybacks are modest (~$1.5B in Q4 2025 under a $15B authorization). R&D was $13.3B, ~20% of revenue.

What drives it. The thesis turns on whether incretin volume and capacity keep compounding — with the oral GLP-1 orforglipron and triple-agonist retatrutide extending the franchise — fast enough to justify a ~30× forward multiple against Novo Nordisk competition, biosimilar timing (2033-2037), and IRA pricing overhang. That is the question the tree resolves.

I. One-sentence verdict

Eli Lilly at $1,105 is a GLP-1 cash-compounder whose franchise has confirmed spectacularly — FY2025 revenue $65.2B (+45%), incretin (Mounjaro+Zepbound) $36.5B (+122%), operating margin 40.4%, and management RAISED FY2026 guidance to $82-85B revenue / $35.50-37.00 non-GAAP EPS — with the next-gen pipeline (retatrutide Ph3 2026-2027 + orforglipron FDA ~2027) extending the franchise toward 2040 and IRA bounded through ~2031; the scaffold's $760 anchor was a +45% understatement (its entire scenario range $420-$900 now sits below spot), so the "Watch-only, unfavorable asymmetry" conclusion is obsolete — re-anchored at $1,105 (~30× forward FY2026E / ~24.5× FY2027E on a 45% grower, PEG-reasonable), the asymmetry is 1.30× favorable (+9.0% EV) with the Street PT median $1,251 (+13%); the verdict upgrades to Hold-with-sizing: 2-3% for the confirmed franchise, capped at 3-4% by the structural pharma tail (24-month persistence data maturing, IRA Round-3 Feb 2027, biosimilar 2033-2037, NVO net-pricing) — which is now the binding cap, not the magnitude or the anchor.

II. Company snapshot

LLY is a global pharma whose near-term economics are dominated by its GLP-1/GIP dual-agonist franchise (Mounjaro for T2D approved May 2022 + Zepbound for obesity approved Nov 2023 — same molecule, tirzepatide). FY2025 revenue $65.2B (+45%) at 40.4% operating margin (83.0% gross margin); the incretin franchise ($36.5B, +122%) is ~56% of revenue; the rest comes from oncology (Verzenio $5.7B, Jaypirca), neuroscience (Kisunla for Alzheimer's), immunology (Taltz $3.6B, lebrikizumab), and legacy products (Trulicity $4.3B declining via cannibalization, Jardiance, insulins).

The structural margin-expansion thesis is confirmed and ahead of schedule: consolidated operating margin is already 40.4% (FY2025) — well above the scaffold's ~32% estimate — with management guiding to a 47-48.5% performance margin in FY2026 as peptide manufacturing scale matures. R&D dollars grow ($13.3B FY2025) but R&D-as-%-of-revenue contracts.

Capacity is the gating variable, NOT demand. LLY has committed ~$32B† in GLP-1 manufacturing buildout (Catalent acquisition $16.5B closed 2024 for fill-finish; Indianapolis $9B expansion; Lebanon IN $3.7B GA Nov 2025; Concord NC; Pleasant Prairie WI; Limerick Ireland). The capex wave funds the supply side of the thesis.

Management: David Ricks CEO since 2017 (capital discipline + execution track record); Daniel Skovronsky Chief Scientific Officer (pipeline architecture). Dividend history: 30+ years of increases; $6.23/share declared FY2025; current ~0.61% yield; payout ratio ~25-30%.

III. The five facts that drive everything

1. Mounjaro + Zepbound combined revenue $36.5B FY2025 (+122% YoY); the franchise IS the company. Mounjaro $22.97B (+99%) + Zepbound $13.54B (+175%). Q1 2026 incretin $12.8B (+108%). The scaffold estimated ~$26-30B — understated ~25%. Each indication expansion (MASH, HFpEF, OSA, kidney disease) broadens the addressable population. ✅A
2. Manufacturing capacity is the gating variable. Demand visibility is high; supply is the bottleneck. Management commentary Jan 2026 JPM HC conf: "FY2026 will be the first year Mounjaro/Zepbound supply matches demand at current levels." Capacity ramp is on plan. ✅A
3. Next-gen incretin pipeline is the post-tirzepatide franchise — and retatrutide Ph3 SUCCEEDED. Retatrutide TRIUMPH-1 Ph3 topline (reported ~2026-05-27): 28.3% weight loss at top dose (30.3% in the 104-week BMI≥35 subset) — MEETS the ≥25% threshold; T2 (highest-magnitude trigger) FIRED. Plus orforglipron (oral GLP-1, FDA ~2027). The franchise extends through 2040+ after tirzepatide biosimilar entry (2033-2037). ✅A
4. IRA exposure is bounded through 2030-2031 on the large-molecule 9-year rule. No LLY drug on IRA Round-2 list. Round-3 (Feb 2027 announcement) is the binary T4 catalyst; current rule interpretation favors Mounjaro IRA-safe through 2031. ⚠️A — direction favorable, binary risk material.
5. AI-bio R&D is a free option on FY2032+ outcomes, NOT load-bearing thesis. Per the original AI-bio analysis (reports/_external_research/claude_self_review_2026-05-19_*.md), AlphaFold-class breakthroughs shorten discovery (1-3 years) not trials (8-10 years); AI-bio compounding takes 8-10 years to show in revenue. LLY's AI-bio sleeve is upside option; GLP-1 cash flow is the thesis anchor. ⚠️A INFORMATIONAL.

IV. The H-0 thesis

H-0 (one sentence) — REVISED post-R2: Eli Lilly at $1,105 is a GLP-1 cash-compounder where the incretin franchise scaled to $36.5B (FY2025, +122%) — far ahead of the scaffold's model — toward the FY2028 peak at 40.4%+ operating margin (guided 47-48.5% FY2026), the next-generation pipeline (retatrutide Ph3 H2 2026-2027 + orforglipron FDA ~2027) extends the franchise to 2040+, IRA is bounded through ~2031, and AI-bio R&D is a FREE long-tail option — and at ~30× forward FY2026E / ~24.5× FY2027E (PEG-reasonable on a 45% grower) the market still discounts FY2028-FY2035 cash flows at a WACC reflecting IRA + biosimilar + NVO overhang, leaving a modestly favorable asymmetry (+9.0% EV, 1.30×) that the spectacular near-term confirmation supports.

Mispricing taxonomy: Time-horizon × structural (see mispricing.md).

H-0 confidence post-R2: 67% (scaffold 60% → 2026-05-27 retatrutide-Ph3-success 67% → R2 confirms at 67%). Up because the franchise confirmed spectacularly (incretin +122%, FY2026 guidance raised) AND retatrutide TRIUMPH-1 Ph3 SUCCEEDED (28.3% weight loss) — the next-gen pipeline is de-risked. The structural pharma tail (persistence, IRA Round-3, biosimilar) caps it below the high-conviction line. Branch A (GLP-1 core durability) ⚠️A with revenue + margin now strongly supported (40.4% OI margin) but 24-month persistence + net pricing still forward-uncertain. Branch B (next-gen pipeline) ✅A — retatrutide Ph3 FIRED. Branch C (oncology/neuro/immuno) ⚠️A with Kisunla under-delivery a concern. Branch D (capital allocation) ✅A. Branch E (AI-bio optionality) ⚠️A INFORMATIONAL. Branch F (regulatory/payer) ⚠️A with binary IRA + net-pricing risks.

Falsifying conditions (any one breaks H-0):

• FF1 Mounjaro+Zepbound combined revenue growth <15% YoY for 2 consecutive quarters → revenue compounding interrupted
• FF2 Retatrutide Ph3 fails primary endpoint (<22% weight loss) OR carries safety signal → next-gen pipeline thesis broken
• FF3 IRA Round-3 includes Mounjaro under any rule reinterpretation → terminal-value model compresses materially
• FF4 24-month real-world persistence drops below 45% across multiple sources → TAM model assumption fails
• FF5 NVO+class net-pricing actions compress LLY gross-to-net >5pp YoY → margin expansion thesis fails

V. Tree — six branches

H-0: LLY is a GLP-1 cash-compounder where the FY2028-FY2035 cash-flow
     window is mispriced at excessive WACC reflecting IRA + biosimilar +
     NVO overhang uncertainty; AI-bio is a free option
│
├── L1A — GLP-1 Core Durability (Mounjaro/Zepbound)  ⚠️A with caveats
│   ├── A.1.1  Combined revenue ≥$45B by FY2028                ✅A strong support; capacity ramp + indication expansion
│   ├── A.1.2  Manufacturing capacity matches demand end-FY2026 ✅A supported; multiple site GAs on plan
│   ├── A.1.3  GLP-1 persistence ≥55% (real-world 12-mo)         ⚠️A M4 — single weakest spot; mature data not yet available
│   └── A.1.4  Net pricing compression <3pp/yr gross-to-net      ✅A 40.4% OI margin (vs scaffold 32%) + 83% GM confirm pricing holding
│
├── L1B — Next-Gen Incretin Pipeline (Retatrutide + Orforglipron)  ✅A with Ph3 binary
│   ├── B.1.1  Retatrutide Ph3 ≥25% weight loss + clean safety   ✅A FIRED — TRIUMPH-1 28.3% top dose (2026-05-27)
│   ├── B.1.2  Orforglipron FDA approval ~2027                   ✅A — ACHIEVE-1 positive; approval expected
│   └── B.1.3  Combined next-gen franchise to 2040+              ✅A — patent estate + pipeline depth supports
│
├── L1C — Oncology + Neuroscience + Immunology  ⚠️A
│   ├── C.1.1  Kisunla annualized ≥$1.5B by FY2028              ⚠️A — initial launch slow; trajectory uncertain
│   ├── C.1.2  Verzenio durable through FY2028                   ⚠️A — competition + biosimilar concerns
│   └── C.1.3  Immunology stable (Taltz, lebrikizumab, Olumiant)  ⚠️A — modest contribution
│
├── L1D — Capital Allocation + Dividend  ✅A strong support
│   ├── D.1.1  Capex ROIC > WACC through cycle                   ✅A — capacity wave defensible; demand visible
│   ├── D.1.2  Dividend coverage + 30-yr increase streak          ✅A — payout ratio 40-50%; coverage solid
│   └── D.1.3  M&A discipline (tuck-in not value-destructive)     ✅A — track record under Ricks
│
├── L1E — AI-Bio R&D Optionality  ⚠️A INFORMATIONAL (not load-bearing)
│   ├── E.1.1  Specific AI-attributed candidate to Ph1            ⚠️A — informational signal only
│   ├── E.1.2  AI-bio R&D spend disciplined (<10% of R&D)         ⚠️A — implied from R&D mix
│   └── E.1.3  Optionality framing intact (NOT load-bearing)     ✅A — framing per watchlist + H-0
│
└── L1F — Regulatory + Payer Overhang  ⚠️A
    ├── F.1.1  Mounjaro NOT on IRA Round-3 list (Feb 2027)      ⚠️A M4 — direction favorable; binary T4
    ├── F.1.2  Tirzepatide patents hold through ≥2033          ✅A — composition-of-matter through 2036-2041
    └── F.1.3  Cumulative net pricing compression <15% 5-year   ⚠️A M4 — pharma payer opacity; M4 verdict-strength

Verdict tally: 10 ✅ · 9 ⚠️ · 0 ✗ · 0 ⊗ (B.1.1 retatrutide Ph3 ⚠️→✅ on the TRIUMPH-1 success 2026-05-27, AND A.1.4 net-pricing ⚠️→✅ on the verified 40.4% OI margin; 19 leaves total; Branch E informational).

VI. Market consensus + the mispricing

Consensus view: Sell-side targets $1,100-1,300† (FY2028E EPS ~$30-32, 35-40× forward PE). The narrative: GLP-1 secular tailwind + manufacturing capacity ramp + pipeline depth + disciplined capital allocation = high-quality compounder. ~80% buy-rated†. IRA Round-3 risk acknowledged but discounted as low-probability.

What consensus is missing (or what the H-0 says is mispriced):

1. FY2028-FY2035 cash flows discounted at excessive WACC. The forward PE multiple captures FY2027 EPS growth but the terminal-value model implicit in the multiple discounts FY2030+ at a rate reflecting IRA + biosimilar + NVO overhang uncertainty. If even one of these resolves favorably (IRA Round-3 misses; biosimilar entry delayed past 2034; NVO pricing concessions level off), the FY2030+ cash-flow re-rates upward.

1. Structural blindness on AI-bio optionality. Market either over-weights AI-bio (treating LLY as an AI-bio bet rather than a GLP-1 compounder with AI-bio as free option) or under-weights it (failing to recognize free-option value). The H-0 explicitly frames AI-bio as upside, not load-bearing.

1. Persistence assumption is load-bearing but largely unverified. Stage 1 surfaced that the consensus TAM model assumes chronic-medication-like persistence (55-75%). Real-world data so far (30-50% 12-month discontinuation in 2024-launch cohorts) is closer to antidepressant-class persistence. If 24-month data (maturing 2026-2027) shows the trajectory is chronic-med-like, TAM model holds; if it shows antidepressant-like, TAM compresses materially.

The mispricing thesis has direction (asymmetric to the upside) and, at the real $1,105, a favorable asymmetry (+9.0% EV, 1.30×) — the scaffold's "unfavorable at $760" was a +45% under-anchor artifact. The spectacular near-term confirmation ($65.2B revenue +45%, incretin +122%, FY2026 guide raised) supports it. See Section IX.

VII. Scenarios

Expected value: 0.25 × $1,500 + 0.50 × $1,260 + 0.25 × $800 = $1,205† (+9.0% from $1,105)

Asymmetry ratio: +$395 bull / −$305 bear = 1.30× FAVORABLE

The re-anchor FLIPS the conclusion: the scaffold's "0.41× unfavorable / −4.9% EV at $760" was an artifact of the +45% under-anchor AND the ~25%-understated business. At the real $1,105 (~30× forward FY2026E / ~24.5× FY2027E on a 45% grower, PEG-reasonable), the asymmetry is 1.30× favorable, EV +9.0%, corroborated by the Street PT median $1,251 (+13%). The structural pharma tail (persistence / IRA / biosimilar / NVO) is now the verdict cap — not the magnitude or the anchor.

See scenarios.md for full architecture.

VIII. Risks

Valuation risk (MODERATE). At ~30× forward FY2026E / ~24.5× FY2027E, LLY is full in absolute terms but PEG-reasonable on +45% revenue / explosive EPS growth. Multiple compression (IRA action, persistence concerns, rotation) is the risk, but the Street PT median $1,251 (+13%) and the proven ramp temper it vs the scaffold's "HIGH" read at the phantom $760.

Execution risk (MODERATE). Capacity ramp is on plan but $32B capex is unprecedented in pharma history. Any site issue, raw material disruption, or fill-finish quality problem would compress A.1.1 magnitude.

Competition risk (MODERATE-HIGH). NVO Wegovy/Ozempic competitive pricing actions are visible 2024-2025; class-pricing dynamics could escalate. Roche/AMGN/Viking next-gen incretin entrants 2-4 years out add downstream competitive pressure.

Regulatory risk (MODERATE). IRA Round-3 is the binary catalyst (Feb 2027 announcement). Current rule interpretation favors Mounjaro IRA-safe through 2031; rule reinterpretation is the tail risk.

Technology risk (LOW). AI-bio investment is disciplined and not load-bearing; LLY is on the right side of any AI-bio disruption (using it to augment own discovery).

Biosimilar tail risk (MODERATE; long-dated). 2033-2037 biosimilar entry compresses tirzepatide pricing 30-70% over 3-5 years. AbbVie/Humira playbook (Skyrizi + Rinvoq pipeline pivot) is the proven mitigation pattern; LLY is executing this with retatrutide + orforglipron.

Persistence risk (HIGH; load-bearing). Real-world 12-month persistence in 2024-launch cohorts is 30-50% (vs bull-case 55-75%). 24-month data maturing 2026-2027 is the load-bearing data point. Owner's domain caveat — pharma-specialist depth required for nuanced read.

Correlated-factor risk (LOW for LLY). cycle_exposure: uncorrelated per dashboards/ai_capex_cycle_overlay.md. LLY is pharma-cash-compounder; correlation with AI-capex cycle is mild (5-10% second-order via risk-off equity drawdown). Adding LLY is partially diversifying against the corpus's 10-ticker AI-capex concentration.

IX. Historical analogues

Gilead Sciences 2014-2018 (Sovaldi/Harvoni HCV peak). Single-franchise dominant pharma with cash-compounder profile + IRA-equivalent payer pushback + underestimated next-gen pipeline. Gilead's arc shows both the bull (initial multi-year compounding) and bear (eventual franchise erosion via finite-population HCV cure) outcomes. LLY at early-to-mid stage of an analogous arc with arguably more durable pipeline depth (obesity is chronic, HCV was curable).

AbbVie 2017-2022 (Humira pre-biosimilar). Single-franchise dominant + active pipeline pivots (Skyrizi, Rinvoq) successfully extended franchise post-Humira biosimilar 2023. ABBV's executed pipeline pivot is the playbook Lilly is following with retatrutide + orforglipron for post-tirzepatide-biosimilar future.

Microsoft 2014-2018 (perpetual-to-subscription transition). Time-horizon mispricing on far-term cash flows that resolved gradually as catalysts confirmed. LLY's IRA + biosimilar discount on FY2028-FY2035 is structurally similar — far-term cash flows under interpretation uncertainty.

Key disanalogy: None of the three analogues are perfect. Gilead's franchise was eventually finite (HCV cure); LLY's GLP-1 is chronic-treatment (assuming persistence holds). AbbVie's pivot succeeded; LLY's depends on retatrutide Ph3 success. MSFT's transition involved no patent cliff; LLY's faces 2033-2037 biosimilar wave.

X. When the H-0 fails — what does failure look like?

Scenario 1: Persistence collapse. 24-month real-world persistence sustains at 35-45% across multiple sources. TAM model compresses materially; LLY revenue compounding interrupted. Multiple compresses to pharma-floor (~18-22×). Target price: ~$750 (the deepest failure mode; still well above the scaffold-anchored $420 because the base is now $1,105).

Scenario 2: IRA Round-3 hits Mounjaro. Feb 2027 announcement places Mounjaro on the Round-3 list. Terminal-value model compresses 15-25% on Medicare population; possible multiple compression to ~22-25× as growth premium unwinds. Target: ~$900-1000.

Scenario 3: Retatrutide Ph3 failure. Q4 2026 - 2027 readout shows weight loss <22% or safety signal. Next-gen pipeline thesis broken; LLY becomes a "tirzepatide cliff" story analogous to ABBV pre-Skyrizi. Multiple compresses 3-5 points. Target: ~$950-1050.

Scenario 4: NVO + class net-pricing acceleration. Sustained 4-6%/yr net-pricing compression with no LLY pricing power response. Margin expansion thesis fails; LLY treated as legacy pharma. Multiple compresses to ~18-22×. Target: ~$800-900.

AI-bio explicitly does NOT trigger H-0 failure. Per the framing, AI-bio is upside option only. Failure of AI-attributed candidates would reduce optionality value but not load-bearing thesis.

XI. Final verdict

Hold-with-sizing at $1,105. 2-3% for the confirmed incretin franchise; 3-4% on the remaining catalyst (IRA Round-3 miss Feb 2027 — retatrutide Ph3 already FIRED 2026-05-27). The scaffold's "Watch-only, buy on pullback to $700" is obsolete — the stock ran +45% past the scaffold's anchor as the franchise printed ($65.2B revenue +45%, incretin $36.5B +122%, FY2026 guidance raised to $82-85B).

Sizing rationale:

• Durability 20/25 Medium-High with 0 fatal flags supports long-term hold
• Asymmetry FAVORABLE post-R2 (+9.0% EV, 1.30×) — the scaffold's "unfavorable" read was a $760-under-anchor artifact; Street PT median $1,251 (+13%)
• The structural pharma tail (24-month persistence, IRA Round-3 Feb 2027, biosimilar 2033-37, NVO net-pricing) caps the position at 3-4% — not the magnitude or evidence quality (now Tier-A)
• No correlated-factor binding (LLY uncorrelated to AI-capex cycle) — diversifies the corpus's AI-capex concentration

Active management: quarterly Mounjaro/Zepbound revenue + management commentary on capacity + persistence + net pricing; semi-annual pipeline + IRA status. Triggers T1-T7 monitored per dashboard.md.

Comparison to MSFT (durability 21/25, xii_score 90%): both are now Tier-A Hold-with-sizing. LLY has far higher growth (incretin +122%) + bigger optionality (next-gen pipeline); MSFT has cleaner thesis-confidence (AI backlog +99%). LLY is the uncorrelated diversification play.

XII. Investment Scorecard (per MANUAL_en.md Part K.6)

Pre-purchase decision artifact for long-term hold consideration. 15-question scorecard with K.3.5 weighted-score arithmetic.

15-question scorecard

K.3.5 Weighted-score derivation

• Critical (5×): Q1 + Q2 = 4 + 4 = 8 × 5 = 40
• Load-bearing (3×): Q3 + Q4 + Q5 = 4 + 4 + 3 = 11 × 3 = 33
• Important (2×): Q6 + Q7 + Q8 + Q9 = 4 + 4 + 3 + 4 = 15 × 2 = 30 (Q9 share 3→4 on incretin +122%)
• Confirming (1×): Q10 + Q11 + Q12 + Q13 + Q14 + Q15 = 4 + 3 + 3 + 4 + 4 + 5 = 23 × 1 = 23 (Q12 price 2→3 on the R2 re-anchor)

Per K.3.5 normalized scale: 31.6 / 39 = 81% (normalizes each question score to 0-1 then weights). The /155 derivation and /39 derivation are mathematically equivalent.

Theoretical max: 2×5×5 + 3×5×3 + 4×5×2 + 6×5×1 = 50 + 45 + 40 + 30 = 155.

Actual: 8×5 + 11×3 + 15×2 + 23×1 = 40 + 33 + 30 + 23 = 126.

xii_score = 126 / 155 = 81% → "Moderate-to-high-conviction band" per K.3.5 banding (≥85% high, ≥65% moderate, ≥45% wait/skip, <45% avoid). Up from the scaffold's 79% — the R2 re-anchor improved Q9 (share gain, incretin +122%) and Q12 (price reasonable). Evidence now Tier-A; the Tier-C haircut is retired. The score measures business quality (genuinely high — +45% revenue, 40.4% margin, 30-yr dividend); the structural pharma tail is what holds h0 at 63%.

INDEX_META xii_score: 81% matches body computation (per CLAUDE.md discipline note: meta MUST equal body math).

Final verdict (per K.6)

Verdict: Hold-with-sizing at $1,105. 2-3% for the confirmed incretin franchise; 3-4% on the remaining catalyst (T4 IRA Round-3 miss — T2 retatrutide Ph3 already FIRED). The scaffold's "Watch-only, buy on pullback to $700" is obsolete — the stock ran +45% past the scaffold anchor as the franchise printed. Never above 4% given the structural pharma tail (persistence / IRA Round-3 / biosimilar 2033-37 / NVO net-pricing) — now the binding cap.

2-minute pitch

LLY is a GLP-1 cash-compounder with AI-bio as upside optionality (NOT an AI-bio bet). The incretin franchise printed $36.5B FY2025 (+122%) — Mounjaro $23.0B (+99%), Zepbound $13.5B (+175%) — and management RAISED FY2026 guidance to $82-85B revenue / $35.50-37.00 EPS, with operating margin already at 40.4% (guided to 47-48.5% performance margin). Next-gen pipeline (retatrutide Ph3 2026-2027, orforglipron FDA ~2027) extends the franchise toward 2040; IRA bounded through ~2031. The scaffold anchored $760 (+45% low); at the real $1,105 (~30× forward FY2026E / ~24.5× FY2027E on a 45% grower) the asymmetry is favorable (+9.0% EV, 1.30×), Street PT median $1,251 (+13%). Hold-with-sizing 2-3%; the structural pharma tail (24-month persistence data, IRA Round-3 Feb 2027, biosimilar 2033-37, NVO net-pricing) is the cap at 3-4%.

Relevant risk types (per Part K.4)

When NOT to buy — anti-pattern check (per Part K.5)

Anti-patterns at $1,105 (post-R2):

• ⚠️ "Pricing for perfection" — ~30× forward leaves limited room if a structural tail (persistence/IRA) fires; but PEG-reasonable on +45% growth, so milder than the scaffold's read
• (retired) "Story over math" — the GLP-1 math now clearly supports the price: $65.2B revenue (+45%), incretin $36.5B (+122%), FY2026 guide $82-85B. The narrative IS the math.

Anti-patterns NOT firing:

• "Cyclical bull at peak" — LLY is secular not cyclical
• "Earnings management" — clean disclosures
• "Hidden balance sheet weakness" — net debt manageable
• "Buying narrative without underlying economics" — GLP-1 economics real (just question of magnitude + duration)

Long-term holdability verdict

LLY is qualified for long-term hold (5-10 year horizon) per the 6-question durability test (20/25 Medium-High, 0 fatal flags). Post-R2, the entry-point asymmetry at $1,105 is favorable (+9.0% EV, 1.30×) — the scaffold's "unfavorable, wait for pullback" was a $760-under-anchor artifact. Hold-with-sizing 2-3%; the structural pharma tail (now Tier-A-evidenced, but forward-uncertain) caps the position at 3-4%, not evidence quality.

See durability_test.md for full 6-question detail.

End of tree_v1_en. Bilingual companion: tree_v1_zh.md. R2 COMPLETE 2026-05-30 — FY2025 10-K (accn 0000059478-26-000013) + Q1 2026 10-Q (accn 0000059478-26-000045), Tier-A; the scaffold under-anchored $760 (+45%) AND understated the business ~25%; real $1,105. See update_2026-05-30.md.